$15.10
0.946.64%
Ult. Agg.: Nov 6, 4:00 PM
The average analyst price target for Apnimed is $50.33, 233.3% above the current price. Of 4 analysts, 4 rate it Buy. Targets range from $41 to $60. The latest change came on Aug 25, 2026, when LifeSci Capital initiated coverage of Apnimed with an Outperform rating and a $50 price target.
Price Target Range — 1 Quarters
Analyst Consensus — 4 Analysts
Rating Trend — Last 9 Months